Basal Cell Carcinoma

Treatment

BCC Prevention

Basal Cell Nevus (Gorlin) Syndrome, > 2 BCCs or 1 for subjects < 20, + 1-2 additional study criterion

SKIN0044
Phase 3 Safety and Efficacy for Prevention of Basal Cell Carcinomas
Pi: Chang Stanford

1 BCC minimum, ≥ 1 cm

SKIN0037
Phase 2 Open label Single arm of Efficacy of Topical Retinostat on Basal Cell Carcinoma
Pi: Sarin Stanford

Concurrently on Vismodegib

SKIN0031
Phase Ib Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma
Pi: Chang Stanford

Advanced Disease

No previous treatment with Hh pathway antagonists (except for Smoothened inhibitors)

SKIN0038
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Pi: Chang Regeneron Pharmaceuticals

SKIN0045
Phase I CX-4945 (Orally - Twice Daily) in Advanced Basal Cell Carcinoma
Pi: Chang Sponsor: Pending